A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.

ABSTRACT:

Aims

Clinicians use multi-gene/biomarker prognostic tests and free online tools to optimize treatment in early ER+/HER2- breast cancer. Here we report the comparison of recurrence risk predictions by CanAssist Breast (CAB), Nottingham Prognostic Index (NPI), and PREDICT along with the differences in the performance of these tests across Indian and European cohorts.

Methods

Current study used a retrospective cohort of 1474 patients from Europe, India, and USA. NPI risk groups were categorized into three prognostic groups, good (GPG-NPI index ≤ 3.4) moderate (MPG 3.41-5.4), and poor (PPG  > 5.4). Patients with chemotherapy benefit of < 2% were low-risk and ≥ 2% high-risk by PREDICT. We assessed the agreement between the CAB and NPI/PREDICT risk groups by kappa coefficient.

SUBMITTER: Gunda A 

PROVIDER: S-EPMC9581859 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature